[
    [
        {
            "time": "2021-11-15",
            "original_text": "Will Pfizer ETFs Soar on Positive COVID-19 Vaccine Updates?",
            "features": {
                "keywords": [
                    "Pfizer",
                    "ETFs",
                    "Positive",
                    "COVID-19",
                    "Vaccine",
                    "Updates"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-16",
            "original_text": "COVID-19 vaccines have ‘proved their merit at this point’: Doctor",
            "features": {
                "keywords": [
                    "COVID-19",
                    "vaccines",
                    "proved",
                    "merit",
                    "Doctor"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-17",
            "original_text": "Countries pushing vaccine IP waivers ‘want to take advantage of the technology’: Fmr. U.S. Commerce Secretary",
            "features": {
                "keywords": [
                    "Countries",
                    "vaccine",
                    "IP",
                    "waivers",
                    "technology",
                    "U.S.",
                    "Commerce",
                    "Secretary"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "government"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-18",
            "original_text": "COVID-19: The U.S. issues advisory for travel to Europe but has no plans for a lockdown",
            "features": {
                "keywords": [
                    "COVID-19",
                    "U.S.",
                    "advisory",
                    "travel",
                    "Europe",
                    "lockdown"
                ],
                "sentiment_score": 0.2,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "travel",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-19",
            "original_text": "Covid-19 Vaccine and Pills Will Push Pfizer’s Revenue Above $100B Next Year, Analyst Says",
            "features": {
                "keywords": [
                    "Covid-19",
                    "Vaccine",
                    "Pills",
                    "Pfizer",
                    "Revenue",
                    "Analyst"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-20",
            "original_text": "4 Reasons Pfizer Is Now the Ultimate COVID-19 Growth Stock",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Ultimate",
                    "COVID-19",
                    "Growth",
                    "Stock"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-21",
            "original_text": "Ukraine to buy 25 mln Pfizer vaccine doses a year over 2022-23",
            "features": {
                "keywords": [
                    "Ukraine",
                    "buy",
                    "Pfizer",
                    "vaccine",
                    "doses",
                    "2022-23"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "international relations"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-22",
            "original_text": "Why FDA Boosters Authorization Could Be More Important for Pfizer and Moderna Than You Might Think",
            "features": {
                "keywords": [
                    "FDA",
                    "Boosters",
                    "Authorization",
                    "Important",
                    "Pfizer",
                    "Moderna"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals",
                    "regulation"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]